Logo

HIV/AIDS

title

Project title: “Sustaining and scaling up the existing national responses for implementation of effective HIV/AIDS prevention activities, improving survival rates of people with advanced HIV infection by strengthening treatment and care interventions in Georgia”. The Global Fund to fight AIDS, TB and Malaria, 01.04.2014 - 01.07.2016.


Project Summary:

a). Project Objectives:

HIV Prevention among most at risk population groups (People who inject drugs (PWIDs), female commercial sex workers (FSWs), Men who have sex with men (MSM) and prisoners); ensuring universal access to Antiretroviral treatment (ART) and related clinical and laboratory monitoring for People living with HIV (PLHIV); providing treatment of hepatitis C with pegilated interferon and ribavirin along with relevant clinical and laboratory monitoring to PLHIV  confected with hepatitis C virus; providing palliative care and supporting operations of self-support centers of PLHIV; scientific and operational studies for assessment of program outcomes.


b). Project implementation:

  • HIV prevention among FSWs, MSM and prisoners;

  • ART provision among AIDS patients;

  • Supporting ART adherence though operation of mobile units;

  • Providing home-based palliative care to PLHIV;

  • Supporting operations of self-support centers of PLHIV;

  • Advocacy for development of supportive environment for implementation of HIV prevention programs;

  • Reduction of HIV related stigma and discrimination among health care workers ;

  • Mobilization of LGBT community for HIV prevention;

  • Implementation of media campaign for reduction of HIV related stigma and discrimination Needle and syringe exchange programs implementation among PWIDs, methadone substitution treatment programs implementation among opioid dependent PWIDs;  

  • Behavioral and biomarkers prevalence assessment and population size estimation studies among PWIDs, FSWs and MSM.


c). Expected results:

Maintaining low HIV prevalence (<5%) among PWIDs and FSWs;

Stabilize HIV prevalence among MSM (<15%);

60% of PLHIV have access to ARV Treatment.